CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
AcTaferon is a novel therapeutic approach that targets specific cells to enhance the efficacy of interferons against cancer and viral infections. By minimizing side effects, it aims to improve treatment outcomes for conditions like influenza.
Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer.
However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses.
Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient.
AcTaferon (Activated-by-Targeting interferon), co-developed by Prof…
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
